Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Pharmaceutical intermediates >  Heterocyclic compound >  4-BroMo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole

4-BroMo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole

Basic information Safety Supplier Related

4-BroMo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole Basic information

Product Name:
4-BroMo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole
Synonyms:
  • 4-BroMo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole
  • 4-bromo-1-(oxan-2-yl)-1H-indazole
  • 4-bromo-1-(oxan-2-yl)indazole
  • 1H-Indazole, 4-bromo-1-(tetrahydro-2H-pyran-2-yl)-
  • 4-Bromo-1-(tetrahydropyran-2-yl)-1H-indazole
  • 4-bromo-1-(oxepan-2-yl)-1H-indazole
CAS:
1022158-35-5
MF:
C12H13BrN2O
MW:
281.15
Mol File:
1022158-35-5.mol
More
Less

4-BroMo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole Chemical Properties

Melting point:
51-52 °C
Boiling point:
405.5±35.0 °C(Predicted)
Density 
1.60±0.1 g/cm3(Predicted)
storage temp. 
Sealed in dry,Room Temperature
pka
-0.22±0.30(Predicted)
Appearance
White to off-white Solid
More
Less

4-BroMo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole Usage And Synthesis

Synthesis

110-87-2

186407-74-9

1022158-35-5

The general procedure for the synthesis of 4-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole from 3,4-dihydro-2H-pyran and 4-bromo-1H-indazole was as follows: 3,4-dihydro-2H-pyran (5.36 mL, 58.57 mmol) was added to a solution of 3,4-dihydro-2H-pyran (5.36 mL, 58.57 mmol) containing 4-bromo-1H-indazole (5.77 g, 29.3 mmol) and 4-bromo-1H-sulphonic acid ( 0.176 g, 1.02 mmol) in a solution of ethyl acetate (60 mL). The reaction mixture was heated and stirred at 70 °C for 16 hours. After the reaction was completed, the mixture was cooled to room temperature and neutralized by adding saturated aqueous sodium bicarbonate solution (50 mL). The organic and aqueous phases were separated and the aqueous phase was extracted with ethyl acetate (10 mL). The organic layers were combined and washed sequentially with saturated aqueous sodium bicarbonate (10 mL) and saturated aqueous sodium chloride (10 mL). The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The resulting brown oil was purified by fast silica gel column chromatography with the eluent being a heptane solution of 10% ethyl acetate. The product fraction was collected and the solvent was evaporated under reduced pressure to give 4-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (7.78 g, 94% yield) as a white solid. The product was confirmed by 1H NMR (400 MHz, CDCl3, 30 °C): δ 1.60-1.88 (3H, m), 2.03-2.23 (2H, m), 2.55 (1H, dddd), 3.73 (1H, dddd), 4.00 (1H, dddd), 5.71 (1H, dddd), 7.19-7.24 (1H, m), and 7.32 (1H, dd), 7.55 (1H, dd), 8.03 (1H, d).

References

[1] Patent: WO2017/182495, 2017, A1. Location in patent: Page/Page column 114-115
[2] Patent: WO2008/51494, 2008, A1. Location in patent: Page/Page column 159
[3] Asian Journal of Chemistry, 2011, vol. 23, # 1, p. 451 - 454
[4] Patent: US2018/111931, 2018, A1. Location in patent: Paragraph 0882; 0883
[5] Synlett, 2009, # 4, p. 615 - 619

4-BroMo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazoleSupplier

ChemShuttle, Inc.
Tel
0510-83588313-811 18800520310
Email
sales@chemshuttle.com
Wuhan Kaymke Chemical Co., Ltd.,
Tel
027-87342388 18086026008
Email
sales@kaymke.com
Shanghai Kahn Pharmaceutical Co., Ltd.
Tel
021-34979681; 17701870669
Email
41513101@qq.com
Shanghai Haozhixiang Biotechnology Co., Ltd
Tel
526763801 13301653310
Email
526763801@qq.com
ChengDu TongChuangYuan Pharmaceutical Co.Ltd
Tel
028-83379370 13880556291
Email
tcy@tcypharm.com